This study investigates the risk factors for severe COVID-19 in patients with immune-mediated rheumatic diseases, focusing on different types of autoimmune conditions and chronic arthritis.
Conducted as a multicenter observational study in Madrid, it involved 523 patients diagnosed with severe COVID-19, analyzing their outcomes based on various demographic and clinical factors.
Key findings revealed that male gender, older age, and certain comorbidities, along with specific medications like corticosteroids and rituximab, were linked to worse COVID-19 outcomes, while treatments like methotrexate showed no negative impact.